Compare DERM & IDE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DERM | IDE |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.3M | 179.6M |
| IPO Year | 2021 | N/A |
| Metric | DERM | IDE |
|---|---|---|
| Price | $4.30 | $11.51 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $13.75 | N/A |
| AVG Volume (30 Days) | ★ 193.9K | 48.8K |
| Earning Date | 11-16-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.83% |
| EPS Growth | ★ 34.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $61,858,000.00 | N/A |
| Revenue This Year | $25.29 | N/A |
| Revenue Next Year | $50.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.20 | N/A |
| 52 Week Low | $4.31 | $11.36 |
| 52 Week High | $9.56 | $14.30 |
| Indicator | DERM | IDE |
|---|---|---|
| Relative Strength Index (RSI) | 36.54 | 46.86 |
| Support Level | $4.31 | $11.87 |
| Resistance Level | $5.50 | $13.95 |
| Average True Range (ATR) | 0.33 | 0.21 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 18.50 | 52.17 |
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.